Japan· JP-4291070M1024
アカラブルチニブ
A acalabrutinib product containing アカラブルチニブ, registered in Japan by アストラゼネカ, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Acalabrutinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EL02 (acalabrutinib), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Acalabrutinib · ATC L01EL02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of acalabrutinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $190.74 in Switzerland — a ×1172 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Acalabrutinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$190.74
- FR France$0.16
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- アカラブルチニブ
- Manufacturer
- アストラゼネカ
- Country
- Japan (JP)
- ATC code
- L01EL02
- ATC class
- Acalabrutinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
375 interactions on record for acalabrutinib.
Graded by severity as the source publishes them — 201 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Acalabrutinib · interactions on record
375 records
- 201 severe
- 174 moderate
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EL02
Acalabrutinib, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b347a833-e26c-4cef-ab01-b3dd30ad5108 GET /v1/drugs/b347a833-e26c-4cef-ab01-b3dd30ad5108?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１００ｍｇ１カプセル",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291070M1024",
"category": "内用薬",
"price_yen": 11705.7,
"generic_name": "アカラブルチニブ",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about acalabrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.